ProKidney (NASDAQ:PROK) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of ProKidney (NASDAQ:PROK) from a hold rating to a sell rating in a report released on Saturday morning.

Several other analysts have also commented on PROK. Jefferies Financial Group upgraded ProKidney to a “strong-buy” rating in a report on Wednesday. HC Wainwright assumed coverage on ProKidney in a research report on Tuesday, December 16th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ProKidney in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.40.

ProKidney Stock Down 1.0%

NASDAQ PROK opened at $1.93 on Friday. ProKidney has a 52 week low of $0.46 and a 52 week high of $7.13. The company has a 50 day moving average price of $2.15 and a 200 day moving average price of $2.42. The firm has a market cap of $580.60 million, a PE ratio of -3.71 and a beta of 1.75.

ProKidney (NASDAQ:PROK) last announced its earnings results on Wednesday, March 18th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.00 million. On average, equities research analysts anticipate that ProKidney will post -0.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ProKidney

Hedge funds and other institutional investors have recently bought and sold shares of the business. Catalyst Funds Management Pty Ltd acquired a new stake in shares of ProKidney in the second quarter worth $36,000. Hudson Bay Capital Management LP acquired a new position in ProKidney during the fourth quarter valued at $101,000. EntryPoint Capital LLC purchased a new stake in ProKidney in the fourth quarter valued at $65,000. Virtu Financial LLC purchased a new stake in ProKidney in the third quarter valued at $203,000. Finally, Two Sigma Investments LP grew its position in ProKidney by 40.4% during the 3rd quarter. Two Sigma Investments LP now owns 99,282 shares of the company’s stock worth $240,000 after purchasing an additional 28,583 shares during the period. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney News Roundup

Here are the key news stories impacting ProKidney this week:

• Positive Sentiment: Jefferies upgraded the stock, providing investor support that can buoy sentiment and trading interest. ProKidney (NASDAQ:PROK) Upgraded at Jefferies Financial Group
• Positive Sentiment: ProKidney reported a narrowed loss and highlighted an upcoming pivotal kidney‑treatment trial — a near‑term binary clinical catalyst that could drive upside if results are favorable. ProKidney narrows loss to $150M as it eyes crucial kidney treatment trial results
• Neutral Sentiment: HC Wainwright reiterated a “Buy” rating and a $12 price target, which is supportive, but the firm also released updated quarterly and multi‑year EPS models for PROK (showing expected losses through 2029 before eventual positive FP2030 guidance). This keeps a bullish analyst voice in the market while signalling longer cash‑burn expectations. HC Wainwright estimates and price target (MarketBeat)
• Negative Sentiment: HC Wainwright cut several FY2026–FY2029 EPS estimates (small downgrades to loss per share forecasts), which can dampen valuation upside and raise concerns about the company’s near‑term operating trajectory. HC Wainwright lowers FY estimates (MarketBeat)
• Negative Sentiment: Wall Street Zen lowered its rating on PROK, adding short‑term negative pressure from another sell‑side view. ProKidney (NASDAQ:PROK) Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: TipRanks flagged new trade‑policy and export/regulatory risks to ProKidney’s supply chain and financial stability, a company‑disclosed risk that can increase execution uncertainty for investors. Trade Policy Risks (TipRanks)

ProKidney Company Profile

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.